8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 30, 2026·SEC
Material company update
Mar 12, 2026·SEC
The Chemours Company(CC)Earnings, Financials & Key Ratios
CC•NYSE
Price updated Jun 17, 2026
SectorBasic MaterialsIndustrySpecialty ChemicalsSub-IndustryIngredients, pigments and specialty minerals
AboutThe Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through four segments: Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure and BaiMax brands for delivering whiteness, brightness, opacity, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging. The Thermal & Specialized Solutions segment offers of refrigerants, thermal management solutions, propellants, foam blowing agents, and specialty solvents. The Advanced Performance Materials segment products portfolio includes various industrial resins, specialty products, membranes, and coatings for consumer electronics, semiconductors, digital communications, transportation, energy, oil and gas, and medical, and others applications. The Chemical Solutions segment comprises a portfolio of industrial chemicals used as raw materials and catalysts for gold production, clean and disinfect, oil and gas, water treatment, electronics, and automotive applications. The company sells its products through direct and indirect channels, as well as through a network of resellers and distributors. The Chemours Company was founded in 2014 and is headquartered in Wilmington, Delaware.Show more
- Revenue$5.81B+0.4%
- EBITDA$335M-55.0%
- Net Income-$386M-548.8%
- EPS (Diluted)-2.56-549.1%
- Gross Margin15.53%-22.0%
- EBITDA Margin5.77%-55.2%
- Operating Margin-0.09%-101.1%
- Net Margin-6.65%-546.8%
- ROE-90.19%-804.7%
CC Key Insights
The Chemours Company (CC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 80 (top 20%)
- ✓Healthy dividend yield of 2.4%
✗Weaknesses
- ✗High debt to equity ratio of 18.3x
- ✗Thin 5Y average net margin of 1.8%
- ✗Expensive at 13.2x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CC Price & Volume
The Chemours Company (CC) stock price & volume — 10-year historical chart
Loading chart...
CC Growth Metrics
The Chemours Company (CC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years0.16%
5 Years3.17%
3 Years-5.26%
TTM0.07%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-2057.14%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1395.86%
Return on Capital
10 Years9.24%
5 Years6.23%
3 Years1.83%
Last Year-0.09%
CC Recent Earnings
The Chemours Company (CC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.05+200.0%
$0.05
Rev
$1.4B-1.3%
$1.4B
Q1 2026
Feb 19, 2026Metric
Actual
Est
EPS
$0.05-43.6%
$0.09
Rev
$1.3B+0.0%
$1.3B
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.20-16.7%
$0.24
Rev
$1.5B+12.5%
$1.3B
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.58+26.1%
$0.46
Rev
$1.6B+4.7%
$1.5B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.05vs $0.05+200.0% | $1.4Bvs $1.4B-1.3% |
| Q1 2026 | Feb 19, 2026 | $0.05vs $0.09-43.6% | $1.3Bvs $1.3B+0.0% |
| Q4 2025 | Nov 6, 2025 | $0.20vs $0.24-16.7% | $1.5Bvs $1.3B+12.5% |
| Q3 2025 | Aug 5, 2025 | $0.58vs $0.46+26.1% | $1.6Bvs $1.5B+4.7% |
Based on last 12 quarters of dataView full earnings history →
CC Peer Comparison
The Chemours Company (CC) competitors in Ingredients, pigments and specialty minerals — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TROX | 1.21B | 7.57 | -2.55 | -5.73% | -12.3% | -30.42% | 2.48 | |
 KRO | 799.62M | 6.95 | -7.24 | -1.47% | -7.12% | -17% | 0.77 | |
 OLN | 2.62B | 23.00 | -62.16 | 3.68% | -1.89% | -6.64% | 1.76 | |
 ASIX | 560.48M | 20.79 | 11.55 | 0.31% | 0.67% | 1.28% | 0.47 | |
 HUN | 2.21B | 12.73 | -8.00 | -5.85% | -5.69% | -8.14% | 0.92 | |
 EMN | 8.25B | 72.12 | 17.59 | -6.71% | 4.62% | 6.69% | 0.84 | |
 CE | 5.73B | 51.23 | -4.81 | -7.16% | -10.79% | -21.51% | 2.89 | |
 AVNT | 3.38B | 36.86 | 41.42 | 0.61% | 4.81% | 6.6% | 0.81 |
Compare CC vs Peers
The Chemours Company (CC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CC Income Statement
The Chemours Company (CC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 6.18B | 6.64B | 5.53B | 4.97B | 6.34B | 6.83B | 6.08B | 5.78B | 5.81B | 5.82B |
Revenue Growth % | 14.5% | 7.36% | -16.75% | -10.08% | 27.69% | 7.66% | -11.02% | -4.87% | 0.45% | 0.07% |
Cost of Goods Sold | 4.43B | 4.67B | 4.46B | 3.9B | 4.96B | 5.21B | 4.77B | 4.63B | 4.91B | 4.94B |
COGS % of Revenue | 71.63% | 70.31% | 80.76% | 78.53% | 78.23% | 76.34% | 78.51% | 80.09% | 84.47% | - |
Gross Profit | 1.75B▲ 0% | 1.97B▲ 12.4% | 1.06B▼ 46.1% | 1.07B▲ 0.4% | 1.38B▲ 29.4% | 1.62B▲ 17.0% | 1.31B▼ 19.2% | 1.15B▼ 11.9% | 902M▼ 21.6% | 878M▲ 0% |
Gross Margin % | 28.37% | 29.69% | 19.24% | 21.47% | 21.77% | 23.66% | 21.49% | 19.91% | 15.53% | 15.08% |
Gross Profit Growth % | 58.02% | 12.37% | -46.07% | 0.38% | 29.43% | 17.02% | -19.18% | -11.87% | -21.63% | - |
Operating Expenses | 682M | 739M | 616M | 619M | 707M | 830M | 1.43B | 708M | 907M | 922M |
OpEx % of Revenue | 11.03% | 11.13% | 11.15% | 12.46% | 11.14% | 12.15% | 23.51% | 12.24% | 15.62% | - |
Selling, General & Admin | 602M | 657M | 0 | 0 | 592M | 710M | 1.29B | 585M | 799M | 823M |
SG&A % of Revenue | 9.74% | 9.9% | - | - | 9.33% | 10.39% | 21.22% | 10.12% | 13.76% | - |
Research & Development | 80M | 82M | 80M | 93M | 107M | 118M | 108M | 109M | 108M | 107M |
R&D % of Revenue | 1.29% | 1.24% | 1.45% | 1.87% | 1.69% | 1.73% | 1.78% | 1.89% | 1.86% | - |
Other Operating Expenses | 0 | 0 | 536M | 526M | 8M | 2M | 31M | 14M | 0 | 1000K |
Operating Income | 1.07B▲ 0% | 1.23B▲ 14.9% | 447M▼ 63.7% | 448M▲ 0.2% | 674M▲ 50.4% | 786M▲ 16.6% | -123M▼ 115.6% | 443M▲ 460.2% | -5M▼ 101.1% | -44M▲ 0% |
Operating Margin % | 17.34% | 18.56% | 8.09% | 9.02% | 10.62% | 11.51% | -2.02% | 7.66% | -0.09% | -0.76% |
Operating Income Growth % | 1016.67% | 14.93% | -63.72% | 0.22% | 50.45% | 16.62% | -115.65% | 460.16% | -101.13% | - |
EBITDA | 1.34B | 1.52B | 715M | 768M | 991M | 1.08B | 184M | 744M | 335M | -132M |
EBITDA Margin % | 21.75% | 22.84% | 12.94% | 15.46% | 15.62% | 15.77% | 3.03% | 12.87% | 5.77% | -2.27% |
EBITDA Growth % | 253.95% | 12.71% | -52.84% | 7.41% | 29.04% | 8.68% | -82.92% | 304.35% | -54.97% | -118.26% |
D&A (Non-Cash Add-back) | 273M | 284M | 268M | 320M | 317M | 291M | 307M | 301M | 340M | -88M |
EBIT | 1.13B | 1.26B | 447M | 447M | 861M | 904M | -110M | 391M | -8M | 154M |
Net Interest Income | -214M | -195M | -208M | -210M | -185M | -163M | -208M | -264M | -269M | -203M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 215M | 195M | 208M | 210M | 185M | 163M | 208M | 264M | 269M | 134M |
Other Income/Expense | -160M | -77M | -427M | -269M | 2M | -45M | -195M | -316M | -272M | -333M |
Pretax Income | 912M▲ 0% | 1.16B▲ 26.6% | 20M▼ 98.3% | 179M▲ 795.0% | 676M▲ 277.7% | 741M▲ 9.6% | -318M▼ 142.9% | 127M▲ 139.9% | -277M▼ 318.1% | -377M▲ 0% |
Pretax Margin % | 14.75% | 17.4% | 0.36% | 3.6% | 10.65% | 10.85% | -5.23% | 2.2% | -4.77% | -6.48% |
Income Tax | 165M | 159M | 72M | -40M | 68M | 163M | -81M | 41M | 109M | 34M |
Effective Tax Rate % | 18.09% | 13.77% | 360% | -22.35% | 10.06% | 22% | 25.47% | 32.28% | -39.35% | -9.02% |
Net Income | 746M▲ 0% | 995M▲ 33.4% | -52M▼ 105.2% | 219M▲ 521.2% | 608M▲ 177.6% | 578M▼ 4.9% | -238M▼ 141.2% | 86M▲ 136.1% | -386M▼ 548.8% | -411M▲ 0% |
Net Margin % | 12.07% | 14.99% | -0.94% | 4.41% | 9.58% | 8.46% | -3.92% | 1.49% | -6.65% | -7.06% |
Net Income Growth % | 10557.14% | 33.38% | -105.23% | 521.15% | 177.63% | -4.93% | -141.18% | 136.13% | -548.84% | -2057.14% |
Net Income (Continuing) | 747M | 996M | -52M | 219M | 608M | 578M | -237M | 86M | -386M | -411M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 5M | 6M | 6M | 2M | 1M | 0 | 2M | 1M | 1M | 1M |
EPS (Diluted) | 3.91▲ 0% | 5.45▲ 39.4% | -0.32▼ 105.9% | 1.32▲ 512.5% | 3.60▲ 172.7% | 3.65▲ 1.4% | -1.60▼ 143.8% | 0.57▲ 135.6% | -2.56▼ 549.1% | -2.73▲ 0% |
EPS Growth % | 9675% | 39.39% | -105.87% | 512.5% | 172.73% | 1.39% | -143.84% | 135.63% | -549.12% | -1395.86% |
EPS (Basic) | 4.04 | 5.62 | -0.32 | 1.33 | 3.69 | 3.72 | -1.60 | 0.58 | -2.57 | - |
Diluted Shares Outstanding | 190.98M | 182.57M | 164.82M | 166.35M | 168.7M | 158.3M | 148.91M | 150.01M | 150.55M | 150.55M |
Basic Shares Outstanding | 184.84M | 176.97M | 164.82M | 164.68M | 164.94M | 155.36M | 148.91M | 149.49M | 150.35M | 150.35M |
Dividend Payout Ratio | 2.95% | 14.87% | - | 74.89% | 26.97% | 26.64% | - | 172.09% | - | - |
CC Balance Sheet
The Chemours Company (CC) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 3.49B | 3.29B | 2.78B | 2.63B | 3.35B | 3.21B | 3.83B | 3.03B | 3B | 2.93B |
Cash & Short-Term Investments | 1.56B | 1.2B | 943M | 1.1B | 1.45B | 1.1B | 1.2B | 713M | 672M | 563M |
Cash Only | 1.56B | 1.2B | 943M | 1.1B | 1.45B | 1.1B | 1.2B | 713M | 672M | 563M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 919M | 861M | 674M | 511M | 720M | 626M | 610M | 770M | 679M | 759M |
Days Sales Outstanding | 54.25 | 47.34 | 44.52 | 37.54 | 41.42 | 33.45 | 36.63 | 48.61 | 42.67 | 52.42 |
Inventory | 935M | 1.15B | 1.08B | 939M | 1.1B | 1.4B | 1.35B | 1.47B | 1.57B | 1.54B |
Days Inventory Outstanding | 77.05 | 89.71 | 88.24 | 87.84 | 80.81 | 98.27 | 103.41 | 116.02 | 116.73 | 114.64 |
Other Current Assets | 83M | 84M | 0 | 78M | 0 | 82M | 705M | 71M | 81M | 70M |
Total Non-Current Assets | 3.8B | 4.07B | 4.48B | 4.45B | 4.21B | 4.43B | 4.42B | 4.49B | 4.38B | 4.34B |
Property, Plant & Equipment | 3.01B | 3.29B | 3.85B | 3.71B | 3.38B | 3.41B | 3.48B | 3.44B | 3.35B | 3.31B |
Fixed Asset Turnover | 2.06x | 2.02x | 1.43x | 1.34x | 1.88x | 2.00x | 1.75x | 1.68x | 1.73x | 1.15x |
Goodwill | 153M | 153M | 153M | 153M | 102M | 102M | 102M | 46M | 46M | 46M |
Intangible Assets | 13M | 28M | 21M | 14M | 6M | 13M | 3M | 3M | 2M | 2M |
Long-Term Investments | 173M | 160M | 162M | 167M | 169M | 175M | 158M | 152M | 212M | 735M |
Other Non-Current Assets | 413M | 391M | 252M | 310M | 376M | 573M | 374M | 556M | 772M | 501M |
Total Assets | 7.29B▲ 0% | 7.36B▲ 0.9% | 7.26B▼ 1.4% | 7.08B▼ 2.4% | 7.55B▲ 6.6% | 7.64B▲ 1.2% | 8.25B▲ 8.0% | 7.51B▼ 8.9% | 7.38B▼ 1.8% | 7.27B▲ 0% |
Asset Turnover | 0.85x | 0.90x | 0.76x | 0.70x | 0.84x | 0.89x | 0.74x | 0.77x | 0.79x | 0.78x |
Asset Growth % | 20.35% | 0.95% | -1.41% | -2.42% | 6.61% | 1.19% | 8% | -8.92% | -1.77% | 1.24% |
Total Current Liabilities | 1.65B | 1.71B | 1.54B | 1.44B | 1.86B | 1.89B | 2.49B | 1.8B | 1.69B | 1.61B |
Accounts Payable | 1.07B | 1.14B | 901M | 820M | 1.14B | 1.21B | 1.13B | 1.12B | 929M | 863M |
Days Payables Outstanding | 88.59 | 88.92 | 73.69 | 76.7 | 83.9 | 84.69 | 86.74 | 88.27 | 69.12 | 70.04 |
Short-Term Debt | 15M | 13M | 134M | 21M | 25M | 43M | 51M | 54M | 104M | 99M |
Deferred Revenue (Current) | 8M | 6M | 7M | 7M | 3M | 0 | 0 | 0 | 0 | 12M |
Other Current Liabilities | 291M | 342M | 148M | 81M | 440M | 325M | 1.13B | 554M | 547M | 506M |
Current Ratio | 2.12x | 1.93x | 1.80x | 1.83x | 1.80x | 1.70x | 1.54x | 1.68x | 1.78x | 1.82x |
Quick Ratio | 1.55x | 1.26x | 1.10x | 1.17x | 1.21x | 0.96x | 1.00x | 0.86x | 0.85x | 0.87x |
Cash Conversion Cycle | 42.71 | 48.13 | 59.08 | 48.67 | 38.33 | 47.03 | 53.31 | 76.35 | 90.29 | 97.02 |
Total Non-Current Liabilities | 4.78B | 4.63B | 5.02B | 4.83B | 4.61B | 4.64B | 5.03B | 5.11B | 5.45B | 5.44B |
Long-Term Debt | 4.1B | 3.96B | 4.03B | 4B | 3.72B | 3.59B | 3.94B | 4.02B | 4.26B | 4.07B |
Capital Lease Obligations | 3M | 2M | 245M | 194M | 179M | 198M | 252M | 227M | 219M | 847M |
Deferred Tax Liabilities | 208M | 217M | 118M | 36M | 49M | 61M | 44M | 35M | 37M | 118M |
Other Non-Current Liabilities | 466M | 448M | 625M | 585M | 656M | 793M | 789M | 824M | 927M | 1.11B |
Total Liabilities | 6.43B | 6.34B | 6.56B | 6.27B | 6.47B | 6.53B | 7.51B | 6.91B | 7.13B | 7.05B |
Total Debt | 4.11B | 3.97B | 4.47B | 4.28B | 3.99B | 3.88B | 4.3B | 4.36B | 4.58B | 4.39B |
Net Debt | 2.56B | 2.77B | 3.53B | 3.17B | 2.54B | 2.78B | 3.1B | 3.64B | 3.91B | 3.83B |
Debt / Equity | 4.75x | 3.89x | 6.43x | 5.25x | 3.68x | 3.50x | 5.82x | 7.20x | 18.27x | 20.33x |
Debt / EBITDA | 3.06x | 2.62x | 6.25x | 5.57x | 4.02x | 3.60x | 23.36x | 5.85x | 13.69x | -33.27x |
Net Debt / EBITDA | 1.90x | 1.83x | 4.93x | 4.13x | 2.56x | 2.58x | 16.83x | 4.90x | 11.68x | -29.00x |
Interest Coverage | 5.24x | 6.46x | 2.15x | 2.13x | 4.65x | 5.55x | -0.53x | 1.48x | -0.03x | 1.15x |
Total Equity | 865M▲ 0% | 1.02B▲ 17.9% | 695M▼ 31.9% | 815M▲ 17.3% | 1.08B▲ 32.8% | 1.11B▲ 2.3% | 739M▼ 33.2% | 605M▼ 18.1% | 251M▼ 58.5% | 216M▲ 0% |
Equity Growth % | 731.73% | 17.92% | -31.86% | 17.27% | 32.76% | 2.31% | -33.24% | -18.13% | -58.51% | -242.78% |
Book Value per Share | 4.53 | 5.59 | 4.22 | 4.90 | 6.41 | 6.99 | 4.96 | 4.03 | 1.67 | 1.43 |
Total Shareholders' Equity | 860M | 1.01B | 689M | 813M | 1.08B | 1.11B | 737M | 604M | 250M | 215M |
Common Stock | 2M | 2M | 2M | 2M | 2M | 2M | 2M | 2M | 2M | 2M |
Retained Earnings | 579M | 1.47B | 1.25B | 1.3B | 1.75B | 2.17B | 1.78B | 1.72B | 1.22B | 1.18B |
Treasury Stock | -116M | -750M | -1.07B | -1.07B | -1.25B | -1.74B | -1.81B | -1.8B | -1.8B | -1.8B |
Accumulated OCI | -442M | -564M | -349M | -310M | -364M | -343M | -274M | -367M | -244M | -244M |
Minority Interest | 5M | 6M | 6M | 2M | 1M | 0 | 2M | 1M | 1M | 1M |
CC Cash Flow Statement
The Chemours Company (CC) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 639M | 1.14B | 650M | 807M | 814M | 755M | 556M | -633M | 264M | 376M |
Operating CF Margin % | 10.33% | 17.17% | 11.76% | 16.24% | 12.83% | 11.05% | 9.15% | -10.95% | 4.55% | - |
Operating CF Growth % | 7.58% | 78.4% | -42.98% | 24.15% | 0.87% | -7.25% | -26.36% | -213.85% | 141.71% | 219.31% |
Net Income | 747M | 996M | -52M | 219M | 608M | 578M | -238M | 86M | -386M | -411M |
Depreciation & Amortization | 273M | 284M | 311M | 320M | 317M | 291M | 307M | 301M | 340M | 250M |
Stock-Based Compensation | 29M | 24M | 19M | 16M | 34M | 27M | 19M | 15M | 0 | 19M |
Deferred Taxes | 83M | 23M | -165M | -120M | -77M | 20M | -158M | -27M | 64M | 68M |
Other Non-Cash Items | 57M | 32M | 399M | 16M | -89M | -58M | 6M | 44M | 68M | 42M |
Working Capital Changes | -466M | -206M | 138M | 356M | 21M | -103M | 620M | -1.05B | 178M | 393M |
Change in Receivables | -88M | 47M | 191M | 12M | -225M | 91M | 0 | -152M | 106M | 217M |
Change in Inventory | -208M | -297M | 116M | 126M | -210M | -294M | 58M | -146M | 0 | -25M |
Change in Payables | -170M | 44M | -169M | 55M | 281M | 105M | -72M | -9M | -165M | -118M |
Cash from Investing | -370M | -487M | -483M | -234M | 220M | -284M | -229M | -353M | -206M | -164M |
Capital Expenditures | -411M | -498M | -481M | -267M | -277M | -307M | -370M | -360M | -213M | -178M |
CapEx % of Revenue | 6.65% | 7.5% | 8.7% | 5.37% | 4.37% | 4.49% | 6.09% | 6.23% | 3.67% | 3.06% |
Acquisitions | 39M | -37M | -10M | 5M | 0 | 0 | 0 | 0 | 7M | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 39M | 46M | 10M | 6M | 509M | 23M | 141M | 7M | 0 | 14M |
Cash from Financing | 353M | -993M | -419M | -449M | -554M | -686M | 172M | -36M | -126M | -88M |
Debt Issued (Net) | 468M | -159M | 88M | -149M | -208M | -80M | 393M | 95M | -60M | -49M |
Equity Issued (Net) | -75M | -628M | -322M | -2M | -173M | -495M | -88M | 0 | 0 | 0 |
Dividends Paid | -22M | -148M | -164M | -164M | -164M | -154M | -149M | -148M | -78M | -54M |
Share Repurchases | -106M | -644M | -322M | -2M | -173M | -495M | -69M | 0 | 0 | 0 |
Other Financing | -18M | -58M | -21M | -134M | -9M | 43M | 16M | 17M | 12M | 15M |
Net Change in Cash | 654M▲ 0% | -355M▼ 154.3% | -258M▲ 27.3% | 162M▲ 162.8% | 446M▲ 175.3% | -247M▼ 155.4% | 503M▲ 303.6% | -1.04B▼ 307.6% | -41M▲ 96.1% | 101M▲ 0% |
Free Cash Flow | 228M▲ 0% | 642M▲ 181.6% | 169M▼ 73.7% | 540M▲ 219.5% | 537M▼ 0.6% | 448M▼ 16.6% | 186M▼ 58.5% | -993M▼ 633.9% | 51M▲ 105.1% | 198M▲ 0% |
FCF Margin % | 3.69% | 9.67% | 3.06% | 10.87% | 8.46% | 6.56% | 3.06% | -17.17% | 0.88% | 3.4% |
FCF Growth % | -10.94% | 181.58% | -73.68% | 219.53% | -0.56% | -16.57% | -58.48% | -633.87% | 105.14% | 124.84% |
FCF per Share | 1.19 | 3.52 | 1.03 | 3.25 | 3.18 | 2.83 | 1.25 | -6.62 | 0.34 | 1.32 |
FCF Conversion (FCF/Net Income) | 0.86x | 1.15x | -12.50x | 3.68x | 1.34x | 1.31x | -2.34x | -7.36x | -0.68x | -0.48x |
Interest Paid | 208M | 206M | 204M | 208M | 180M | 164M | 223M | 267M | 0 | 0 |
Taxes Paid | 79M | 75M | 85M | 78M | 149M | 131M | 54M | 73M | 0 | 0 |
CC Key Ratios
The Chemours Company (CC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 153.97% | 105.57% | -6.06% | 29.01% | 64.1% | 52.81% | -25.79% | 12.8% | -90.19% | -163.42% |
Return on Invested Capital (ROIC) | 26.07% | 25.62% | 8.37% | 8.19% | 13.29% | 15.71% | -2.39% | 8.22% | -0.09% | -0.8% |
Gross Margin | 28.37% | 29.69% | 19.24% | 21.47% | 21.77% | 23.66% | 21.49% | 19.91% | 15.53% | 15.08% |
Net Margin | 12.07% | 14.99% | -0.94% | 4.41% | 9.58% | 8.46% | -3.92% | 1.49% | -6.65% | -7.06% |
Debt / Equity | 4.75x | 3.89x | 6.43x | 5.25x | 3.68x | 3.50x | 5.82x | 7.20x | 18.27x | 20.33x |
Interest Coverage | 5.24x | 6.46x | 2.15x | 2.13x | 4.65x | 5.55x | -0.53x | 1.48x | -0.03x | 1.15x |
FCF Conversion | 0.86x | 1.15x | -12.50x | 3.68x | 1.34x | 1.31x | -2.34x | -7.36x | -0.68x | -0.48x |
Revenue Growth | 14.5% | 7.36% | -16.75% | -10.08% | 27.69% | 7.66% | -11.02% | -4.87% | 0.45% | 0.07% |
Related:CC Dividend History·CC Revenue History·CC Price History·CC P/E History·CC Financial Ratios·CC Institutional Holders
CC SEC Filings & Documents
The Chemours Company (CC) SEC filings — annual & quarterly reports (10-K, 10-Q)
CC Frequently Asked Questions
The Chemours Company (CC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
The Chemours Company (CC) reported $5.82B in revenue for fiscal year 2025. This represents a 21% decrease from $7.37B in 2012.
The Chemours Company (CC) grew revenue by 0.4% over the past year. Growth has been modest.
The Chemours Company (CC) reported a net loss of $411.0M for fiscal year 2025.
Dividend & Returns
Yes, The Chemours Company (CC) pays a dividend with a yield of 2.35%. This makes it attractive for income-focused investors.
The Chemours Company (CC) has a return on equity (ROE) of -90.2%. Negative ROE indicates the company is unprofitable.
The Chemours Company (CC) generated $198.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.